Yes.: Alemtuzumab is a monoclonal antibody directed against a marker on some lymphocytes. It has proven activity against some stages of chronic lymphocytic leukemia (and related diseases) and also on some stages of multiple sclerosis. Alemtuzumab is the generic name. The formulation for MS has the trade name Lemtrada; the one for CLL has the trade name Campath (alemtuzumab).
Answered 11/28/2017
3.2k views
3 doctors weighed in across 3 answers
A doctor has provided 1 answer
A doctor has provided 1 answer
5 doctors weighed in across 2 answers
90,000 U.S. doctors in 147 specialties are here to answer your questions or offer you advice, prescriptions, and more.
Ask your question